Beyond highly developed pharma markets!
Wild card access to less explored, high entry barrier territories
Sameer Kolhe, President, Maypharm Life Sciences highlights that COVID-19 brings some ‘challenging’ markets within reach for the Indian pharma manufacturers
Some territories have always remained illusive for Indian Pharmaceutical companies due to high entry barriers. These markets are important for next phase of growth and how can COVID 19 be a catalyst in this effort.
Here is an article from Express Pharma written by Sameer Kolhe with a special focus on Brazil.